Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.
Sharon M Castellino, Hongli Li, Alex F Herrera, Michael LeBlanc, Susan K Parsons, Joseph M Unger, Angela Punnett, David Hodgson, Frank G Keller, Richard A Drachtman, Adam Lamble, Christopher J Forlenza, Andrew Doan, Sarah C Rutherford, Andrew M Evens
Published: 202610.1200/JCO-25-00203
Abstract
We present a subset analysis on the adolescent cohort of the S1826 randomized phase three trial, comparing nivolumab, doxorubicin, vinblastine, dacarbazine (N-AVD) to brentuximab vedotin-AVD (BV-AVD) in newly diagnosed advanced-stage (AS, stages III…
Preview only. Read the full abstract at the source